John Lechleiter, chief executive officer of Eli Lilly & Co., talks with Bloomberg's Carol Massar and Julie Hyman from Indianapolis about the drugmaker's agreement to buy ImClone Systems Inc. for $6.5 billion. Lilly's $70-a-share bid for ImClone, the biotechnology company controlled by billionaire Carl Icahn, tops Bristol-Myers Squibb Co.'s hostile bid of $62 a share.
Rating:  (0 ratings) |
Views: 12 |
Added: Oct 6, 2008 |
| Category: Business |
|
|
|